Applied Clinical Trials Magazine

09/12/2024

Compliance with diverse clinical trial payment and data standards requires specialized skills.

09/12/2024

An overview of the advantages of implementing AI into clinical development and the obstacles that prevent its widespread adoption.

09/11/2024

📍2024 Veeva Systems R&D and Quality Summit Coverage
Dee DeOliviera, senior director, global regulatory operations, Cerevel Therapeutics (now part of AbbVie) highlights her experience in operations and how to address increased oversight from regulators

DeOliviera, senior director, global regulatory operations, Cerevel (now part of AbbVie) highlights her experience in regulatory operations and how to address increased oversight from regulators.

09/10/2024

Analysis confirms there is a relatively high degree of variability in risk planning results across studies.

09/10/2024

In a fireside chat with ACT editor Andy Studna, Burks, vice president, site solutions highlights her career path and streamlining workflows between sites and sponsors.

09/09/2024

Improving accessibility drives faster and more efficient patient enrollment and a more diverse trial population 🖋️Iddo Peleg, CEO and cofounder, Yonalink

Improving accessibility drives faster and more efficient patient enrollment and a more diverse trial population.

09/09/2024

Across two clinical trials in the QWINT program, efsitora showed non-inferior A1C reduction compared to other frequently used daily insulins.

09/05/2024

While measuring and managing site costs can be challenging, these codes can aid in accounting for labor expenses, budgeting for sponsors, and more. 🖋️ Norman Goldfarb, executive director of the Site Council and executive director of the Clinical Research Interoperability Standards Initiative (CRISI)

While measuring and managing site costs can be challenging, these codes can aid in accounting for labor expenses, budgeting for sponsors, and more.

09/05/2024

Lu AG09222 shows promise as first-in-class medication that prevents , , and , which are considered to be surrogate markers of attacks.

Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.

09/04/2024

Latest Phase II data of Valneva and Pfizer’s VLA15 are consistent with those reported following the first booster dose.

09/03/2024

First FDA submission of nipocalimab is based on positive results from the Phase III Vivacity-MG3 program.

08/29/2024

The clinical program consists of two studies, MELODY-2 and MELODY-3, from which results are expected in Q4 2025.

08/28/2024

First-in-class option to reduce frequency and severity of VMS due to menopause will now be evaluated in women with breast cancer receiving adjuvant endocrine therapy.

08/27/2024

Observational cohort study evaluated nearly 900 school-age children to identify how these symptoms vary by age and how they can assist in future research of

Observational cohort study evaluated nearly 900 school-age children to identify how these symptoms vary by age and how they can assist in future research of long COVID.

08/23/2024

The pivotal Phase III OASIS 1 and 2 studies both met all primary endpoints with elinzanetan reducing symptoms over 12 weeks compared to placebo.

08/22/2024

The Tufts Center for the Study of Drug Development (Tufts CSDD) is conducting a study on investigative site perspectives and burden associated with Direct-to-Patient (DTP) shipment of study treatments and supplies.

08/21/2024

🚨Our July/August issue is LIVE🚨
What's next for DCTs?🔺The evolution of 🔺The benefits of embracing ‘desirable difficulties’🔺and so much more right here➡️ https://www.appliedclinicaltrialsonline.com/journals/applied-clinical-trials/applied-clinical-trials-08-01-2024

08/20/2024

📹 In this part of this video interview, Melissa Easy, VP commercial, digital products & solutions, IQVIA shares what excites her most about the future of clinical technology

In the fifth and final part of this video interview, Melissa Easy, VP commercial, digital products & solutions, IQVIA shares what excites her most about the future of clinical technology.